BackInsight Molecular Diagnostics Overview

Insight Molecular Diagnostics Other Liabilities

Track Insight Molecular Diagnostics's other liabilities ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00

Peer average

Loading

Insight Molecular Diagnostics Other Liabilities History

Loading

Insight Molecular Diagnostics vs. peers: Other Liabilities Comparison

Loading

Insight Molecular Diagnostics Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Insight Molecular Diagnostics (IMDX) FAQ

Insight Molecular Diagnostics (IMDX) currently reports a other liabilities of $0 as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Insight Molecular Diagnostics's other liabilities history and peer comparisons.

Insight Molecular Diagnostics's other liabilities changed from $0 to $0 (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Insight Molecular Diagnostics reported $0 in other liabilities as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other liabilities of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Insight Molecular Diagnostics, and consider following IMDX for alerts when major investors trade the stock.

Insight Molecular Diagnostics is classified in the Technology sector. On other liabilities, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Technology are usually more informative than comparing IMDX with unrelated industries.